TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Guilin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration of Foscarnet Sodium Injection. This approval allows the drug to be used for treating cytomegalovirus retinitis in AIDS patients and acyclovir-resistant herpes simplex virus infections in patients with compromised immune systems, potentially strengthening the company’s position in the pharmaceutical market.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company based in China, operating in the pharmaceutical industry. The company focuses on developing and manufacturing a wide range of pharmaceutical products, with a market focus on both domestic and international markets.
Average Trading Volume: 5,642,817
Technical Sentiment Signal: Buy
Current Market Cap: HK$75.4B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.